{"entity":{"id":"avistone-biotechnology","kind":"company","name":"Avistone Biotechnology","aka":["Avistone Biotechnology Co., Ltd."],"tldr":"Avistone Biotechnology is a China-based biotechnology company running 5 late-stage cancer trials of PLB1004, Vebreltinib and ANS02 in non-small-cell lung cancer.","summary":"Avistone Biotechnology, based in Beijing, China, is a biotechnology company. A commercialisation-stage innovative biopharmaceutical company (Chinese name Anvistone, formerly Beijing Puyuan Anvistone) focused on developing precision cancer medicines, with a manufacturing partner in Ningbo. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials, testing PLB1004, Vebreltinib and ANS02 in non-small-cell lung cancer. The largest, NCT07538804 (A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer), plans to enrol 294 participants. On 30 April 2026 China's drug regulator granted conditional approval to its EGFR exon 20 insertion inhibitor (brand name Anbirui), tested in the single-arm KANNON trial (NCT06015503), for adults with advanced non-small-cell lung cancer carrying that mutation whose disease progressed on or after platinum chemotherapy or who cannot tolerate it. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.avistonebio.com"},{"label":"Avistone: conditional approval in China for EGFR exon 20 insertion lung cancer (30 April 2026, Chinese)","url":"https://www.avistonebio.com/news_details/112.html"},{"label":"ClinicalTrials.gov: trials led by Avistone Biotechnology","url":"https://clinicaltrials.gov/search?lead=Avistone%20Biotechnology%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["vebreltinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06343064","nct06574347","nct07538804","nct06015503","nct07336732"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Freshened 29 October 2026 from the company's Chinese newsroom (approval announcement dated 30 April 2026). The approved drug's English generic name is not given on the Chinese page and is not supplied here. No IPO, acquisition or renaming found on the company site or in a Hong Kong exchange name search."],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Beijing","country":"CN","companyType":"biotech","website":"https://www.avistonebio.com","founded":2012,"stage":"growth","investors":[],"funding":[]},"route":"/companies/avistone-biotechnology/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"vebreltinib","kind":"drug","name":"Vebreltinib","route":"/drugs/vebreltinib/"}],"trial":[{"id":"nct06015503","kind":"trial","name":"A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)","route":"/trials/nct06015503/"},{"id":"nct07285148","kind":"trial","name":"A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer","route":"/trials/nct07285148/"},{"id":"nct07538804","kind":"trial","name":"A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer","route":"/trials/nct07538804/"},{"id":"nct07336732","kind":"trial","name":"Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations","route":"/trials/nct07336732/"},{"id":"nct06281964","kind":"trial","name":"Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.","route":"/trials/nct06281964/"},{"id":"nct07063329","kind":"trial","name":"Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive","route":"/trials/nct07063329/"},{"id":"nct06574347","kind":"trial","name":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.","route":"/trials/nct06574347/"},{"id":"nct06343064","kind":"trial","name":"Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI","route":"/trials/nct06343064/"},{"id":"nct06970782","kind":"trial","name":"Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur","route":"/trials/nct06970782/"}],"company":[{"id":"apollomics","kind":"company","name":"Apollomics","route":"/companies/apollomics/"}]}}